Close
Help
Home Journals Subjects About My LA Reviewers Authors News Submit
Username: Password:
.
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


Enter the three character code
Visual CAPTCHA
Privacy Statement
 
 
 
 
 
 

Biomarkers in Bladder Cancer: Present Status and Perspectives

Authors: Wun-Jae Kim, Soongang Park and Yong-June Kim
Publication Date: 27 Mar 2007
Biomarker Insights 2007:2 95-105

Wun-Jae Kim1, Soongang Park2 and Yong-June Kim2

1Department of Urology, Chungbuk National University, College of Medicine and Institute for Tumor Research, South Korea. 2Department of Urology, Chungbuk National University, College of Medicine, Cheongju, South Korea.

Abstract: Bladder cancers are a mixture of heterogeneous cell populations, and numerous factors are likely to be involved in dictating their recurrence, progression and the patient’s survival. For any candidate prognostic marker to have considerable clinical relevance, it must add some predictive capacity beyond that offered by conventional clinical and pathologic parameters. Here, the current situation in bladder cancer research with respect to identification of suitable prognostic markers is reviewed. A number of individual molecular markers that might predict bladder cancer recurrence and progression have been identified but many are not sufficiently sensitive or specific for the whole spectrum of bladder cancer diseases seen in routine clinical practice. These limitations have led to interest in other molecular parameters that could enable more accurate prognosis for bladder cancer patients. Of particular interest is the epigenetic silencing of tumor suppressor genes. Since the methylation of these genes can correlate with a poor prognosis, the methylation profile may represent a new biomarker that indicates the risk of transitional cell carcinoma development. In addition, bladder cancer research is likely to be revolutionized by high-throughput molecular technologies, which allow rapid and global gene expression analysis of thousands of tumor samples. Initial studies employing these technologies have considerably expanded our ability to classify bladder cancers with respect to their survivability. Future microarray analyses are likely to reveal particular gene expression signatures that predict the likelihood of bladder cancer progression and recurrence, as well as patient’s survival and responsiveness to different anti-cancer therapies, with great specificity and sensitivity.

Categories: Cancer , Urology , Biomarkers



Send to EndnoteView on Pubmed